New England Journal of Medicine· 2014Q1· Clinical trial
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- 2,513citations
- Q1SCImago
- 2014year
Short summary
Adding bevacizumab to standard radiotherapy and temozolomide for newly diagnosed glioblastoma significantly extended progression-free survival by over 4 months, but did not improve overall survival.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Genetics
GeneticsMedicine